Search for: "Eli, Inc."
Results 681 - 700
of 999
Sort by Relevance
|
Sort by Date
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging novelty:… [read post]
4 Aug 2010, 12:21 am
Roxane Laboratories Inc. [read post]
28 Jul 2010, 5:04 pm
Eli Lilly & Co. [read post]
28 Jul 2010, 2:32 pm
Eli Lilly and Company (Fed. [read post]
28 Jul 2010, 12:06 am
Sandoz, Inc. [read post]
26 Jul 2010, 9:22 pm
Discussion Reports Julia Geneuss, Jan Philipp Book, Boris Burghardt, & Oliver Schüttpelz, Core Crimes Inc.: Panel Discussion Reports from the Conference on ‘Transnational Business and International Criminal Law’, held at Humboldt University Berlin, 15–16 May 2009 [read post]
21 Jul 2010, 9:09 am
http://tinyurl.com/2ebwzx5 Eli Lilly Co. v. [read post]
21 Jul 2010, 4:33 am
Skyy Spirits, Inc., 225 F. 3d 1068 (9th Cir. 2000). [read post]
15 Jul 2010, 2:39 pm
Wyeth, Inc., 613 F. [read post]
13 Jul 2010, 10:56 am
(Eugene Volokh) The case is Fox Television, Inc. v. [read post]
7 Jul 2010, 5:00 am
Butler is also a director at Cooper Industries and ConAgra Foods, Inc. [read post]
7 Jul 2010, 3:28 am
Since the issue was actually and necessarily decided in the arbitration, in which CISEF had a full and fair opportunity to litigate the issue, CISEF and the other plaintiffs, who are admittedly in privity with it, are precluded from relitigating it herein (see Kaufman v Eli Lilly & Co., 65 NY2d 449, 455 [1985]; Active Media Servs., Inc. v Grant Prideco, Inc., 35 AD3d 165 [2006]). [read post]
2 Jul 2010, 5:00 pm
Sulzer Orthopedics, Inc., ___ Fed. [read post]
1 Jul 2010, 1:32 pm
Grassley letters are available in the continuation of this blog entryBelow are links to the letters sent by Grassley to: Abbott Laboratories Amgen AstraZeneca Pharmaceuticals Boehringer Bristol-Myers Squibb Company Eisai Corporation of America Eli Lilly and Company Forest Laboratories GlaxoSmithKline Hoffman-La Roche Inc. [read post]
1 Jul 2010, 6:30 am
Senator Charles Grassley asked 16 drugmakers, including Pfizer Inc., AstraZeneca Plc and Eli Lilly & Co., to reveal how they treat whistleblowers who file complaints under the False Claims Act.Grassley, an Iowa Republican, sent letters June 28 that posed eight questions such as how companies notify employees of the law, how they treat whistleblowers and what changes they have made in response to a 2009 law extending anti-retaliation protections. [read post]
1 Jul 2010, 5:00 am
Eli Lilly & Co., 394 N.E.2d 1369 (Ill. [read post]
24 Jun 2010, 5:00 am
Eli Lilly & Co., 84 F.R.D. 230 (D.S.C. [read post]
17 Jun 2010, 6:47 am
Abbott Laboratories, Inc. [read post]
17 Jun 2010, 5:00 am
(quoting BMW, Inc. v. [read post]
16 Jun 2010, 7:43 am
Features of note include "Invalidity for lack of Industrial Application - The Court of Appeal hands down its decision in ELi Lilly & Co. v Human Genome Sciences Inc", by the IPKat's friend and IPSoc founder Charlotte Weekes (now with Pinsent Masons).The new UK coalition government is publishing an emergency budget next Tuesday, 22 June. [read post]
